Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about BDRX, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Sirolimus | Familial Adenomatous Polyposis (FAP) | Phase 3 · NCT06950385 | Recruiting |
| Encapsulated Rapamycin | Familial Adenomatous Polyposis | Phase 2 · NCT04230499 | Active not recruiting |
| Panobinostat Nanoparticle Formulation MT | Recurrent Glioblastoma | Phase 1 · NCT05324501 | Terminated |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
BDRX holds $3.2M in cash and short-term investments and burns about $1.7M/quarter from operations, an estimated runway of 5.6 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 55 · Elevated
· Our requirement for additional financing in the short-term represents a material uncertainty that raises substantial doubt about our ability to continue as a going concern.20-F, Mar 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BDRX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| SABBY MANAGEMENT, LLC | 5%+ holder (13G) | 217,600 | 0.00% | 2025-12-31 |
| Armistice Capital, LLC | Institution (13G, 5%+) | 26,166 | 0.00% | 2026-06-30 |
Share count 225,817,808,922 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BDRX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →